Guru Sonpavde

Guru Sonpavde

UNVERIFIED PROFILE

Are you Guru Sonpavde?   Register this Author

Register author
Guru Sonpavde

Guru Sonpavde

Publications by authors named "Guru Sonpavde"

Are you Guru Sonpavde?   Register this Author

100Publications

2494Reads

35Profile Views

Enfortumab Vedotin, a fully human monoclonal antibody against Nectin 4 conjugated to monomethyl auristatin E for metastatic urothelial Carcinoma.

Expert Opin Investig Drugs 2019 Sep 17:1-6. Epub 2019 Sep 17.

Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute , Boston , MA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13543784.2019.1667332DOI Listing
September 2019

Expression and Role of Methylenetetrahydrofolate Dehydrogenase 1 Like (MTHFD1L) in Bladder Cancer.

Transl Oncol 2019 Aug 7;12(11):1416-1424. Epub 2019 Aug 7.

Department of Pathology, The University of Alabama at Birmingham, Birmingham, AL, USA; O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.tranon.2019.07.012DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6700437PMC
August 2019

Prostate cancer cells hyper-activate CXCR6 signaling by cleaving CXCL16 to overcome effect of docetaxel.

Cancer Lett 2019 Jul 8;454:1-13. Epub 2019 Apr 8.

Department of Microbiology, Biochemistry and Immunology, Morehouse School of Medicine, Atlanta, GA, 30310, USA; Cancer Health Equity Institute, Morehouse School of Medicine, Atlanta, GA, 30310, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S03043835193021
Publisher Site
http://dx.doi.org/10.1016/j.canlet.2019.04.001DOI Listing
July 2019

Advanced urothelial cancer: a radiology update.

Abdom Radiol (NY) 2019 Jul 30. Epub 2019 Jul 30.

Department of Imaging, Dana Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA, 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00261-019-02148-3DOI Listing
July 2019

A new subtyping model for residual invasive disease after cisplatin-based neoadjuvant chemotherapy for muscle invasive bladder cancer.

Transl Androl Urol 2019 Jul;8(Suppl 3):S254-S256

Genitourinary Oncology Division, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/tau.2018.12.10DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6642977PMC
July 2019

Utility of cell-free nucleic acid and circulating tumor cell analyses in prostate cancer.

Asian J Androl 2018 May-Jun;20(3):230-237

Dana Farber Cancer Institute, Genitourinary Oncology Section, Boston, MA 02215, USA.

View Article

Download full-text PDF

Source
http://www.ajandrology.com/text.asp?2018/20/3/230/227854
Publisher Site
http://dx.doi.org/10.4103/aja.aja_1_18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5952476PMC
June 2019

Taxane-based Combination Therapies for Metastatic Prostate Cancer.

Eur Urol Focus 2019 May 21;5(3):369-380. Epub 2017 Dec 21.

Genitourinary Oncology Section, Dana Farber Cancer Institute, Boston, MA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euf.2017.11.009DOI Listing
May 2019

Impact of tumor, treatment, and access on outcomes in bladder cancer: Can equal access overcome race-based differences in survival?

Cancer 2019 Apr 11;125(8):1319-1329. Epub 2019 Jan 11.

Division of Urological Surgery and Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/cncr.31926
Publisher Site
http://dx.doi.org/10.1002/cncr.31926DOI Listing
April 2019

Rare Genitourinary Malignancies: Current Status and Future Directions of Immunotherapy.

Eur Urol Focus 2019 Mar 22. Epub 2019 Mar 22.

Genitourinary Oncology Division, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euf.2019.03.011DOI Listing
March 2019

Predictive Role of Computed Tomography Texture Analysis in Patients with Metastatic Urothelial Cancer Treated with Programmed Death-1 and Programmed Death-ligand 1 Inhibitors.

Eur Urol Oncol 2019 Mar 9. Epub 2019 Mar 9.

Department of Imaging, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euo.2019.02.002DOI Listing
March 2019

Systemic treatments for metastatic urothelial carcinoma.

Expert Opin Pharmacother 2019 02 9;20(2):201-208. Epub 2018 Nov 9.

b Lank Center for Genitourinary Oncology , Dana-Farber Cancer Institute , Boston , MA , USA.

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14656566.2018.1
Publisher Site
http://dx.doi.org/10.1080/14656566.2018.1544242DOI Listing
February 2019

Treatment Approaches for Cisplatin-Ineligible Patients with Invasive Bladder Cancer.

Curr Treat Options Oncol 2019 Feb 11;20(2):12. Epub 2019 Feb 11.

Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, DANA 1230, Boston, MA, 02215, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11864-019-0609-6
Publisher Site
http://dx.doi.org/10.1007/s11864-019-0609-6DOI Listing
February 2019

Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.

Eur Urol 2019 01 16;75(1):88-99. Epub 2018 Apr 16.

Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, School of Medicine, Baltimore, MD, USA; Department of Urology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, School of Medicine, Baltimore, MD, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2018.03.028DOI Listing
January 2019

Conceptual Framework for Therapeutic Development Beyond Anti-PD-1/PD-L1 in Urothelial Cancer.

Am Soc Clin Oncol Educ Book 2019 Jan 17;39:284-300. Epub 2019 May 17.

4 Dana Farber Cancer Institute, Harvard Medical School, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_237449DOI Listing
January 2019

Statin Use and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Treated with Abiraterone Acetate.

Eur Urol Focus 2018 12 8;4(6):874-879. Epub 2017 Apr 8.

Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy; Istituto Zooprofilattico Sperimentale del Mezzogiorno, Portici, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euf.2017.03.015DOI Listing
December 2018

Immunotherapy for advanced penile cancer - rationale and potential.

Nat Rev Urol 2018 Dec;15(12):721-723

Genitourinary Oncology Division, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41585-018-0083-0DOI Listing
December 2018

Characterizing trends in treatment modalities for localized muscle-invasive bladder cancer in the pre-immunotherapy era.

World J Urol 2018 Nov 14;36(11):1767-1774. Epub 2018 Jun 14.

Division of Urological Surgery, Brigham and Women's Hospital, Harvard Medical School, 45 Francis St, ASB II-3, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00345-018-2371-yDOI Listing
November 2018

Evaluating the cost of surveillance for non-muscle-invasive bladder cancer: an analysis based on risk categories.

World J Urol 2018 Nov 16. Epub 2018 Nov 16.

Division of Urology, Harvard Medical School, Brigham and Women's Hospital, 45 Francis Street, Boston, MA, 02115, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00345-018-2550-x
Publisher Site
http://dx.doi.org/10.1007/s00345-018-2550-xDOI Listing
November 2018

Cabozantinib for Progressive Metastatic Castration-resistant Prostate Cancer Following Docetaxel: Combined Analysis of Two Phase 3 Trials.

Eur Urol Oncol 2018 Nov 30. Epub 2018 Nov 30.

Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euo.2018.11.006DOI Listing
November 2018

Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing.

J Clin Oncol 2018 Oct 19:JCO1800328. Epub 2018 Oct 19.

Thomas P. Slavin, Kar Wing Kevin Tsang, Susan L. Neuhausen, Stacy W. Gray, and Jeffrey N. Weitzel, City of Hope, Duarte; Kimberly C. Banks, Darya Chudova, Justin I. Odegaard, Rebecca J. Nagy, Christine E. Lee, and Richard B. Lanman, Guardant Health, Redwood City; Razelle Kurzrock, University of California, San Diego, Moores Cancer Center, San Diego, CA; Geoffrey R. Oxnard, Dana-Farber Cancer Institute; Aditya Bardia, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA; Massimo Cristofanilli, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Angel A. Rodriguez, Houston Methodist Hospital; Funda Meric-Bernstam, The University of Texas MD Anderson Cancer Center, Houston, TX; Brian Leyland-Jones, Avera Cancer Institute, Sioux Falls, SD; Mike F. Janicek, Arizona Oncology Associates Gynecology Oncology, Scottsdale, AZ; Michael Lilly, Medical University of South Carolina, Charleston, SC; and Guru Sonpavde, The University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.18.00328
Publisher Site
http://dx.doi.org/10.1200/JCO.18.00328DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6286162PMC
October 2018

Can RECIST response predict success in phase 3 trials in men with metastatic castration-resistant prostate cancer?

Prostate Cancer Prostatic Dis 2018 09 1;21(3):419-430. Epub 2018 Jun 1.

Department of Medicine, School of Medicine, Duke University, Durham, NC, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41391-018-0049-6
Publisher Site
http://dx.doi.org/10.1038/s41391-018-0049-6DOI Listing
September 2018

A Role for De Novo Purine Metabolic Enzyme PAICS in Bladder Cancer Progression.

Neoplasia 2018 09 15;20(9):894-904. Epub 2018 Aug 15.

Department of Pathology, University of Alabama at Birmingham, Birmingham, AL, USA; Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USA; Informatics Institute, University of Alabama at Birmingham, Birmingham, AL, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S14765586183018
Publisher Site
http://dx.doi.org/10.1016/j.neo.2018.07.006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6098199PMC
September 2018

Treating Patients With Bladder Cancer: Is There an Ethical Obligation to Include Smoking Cessation Counseling?

J Clin Oncol 2018 Sep 13:JCO1800577. Epub 2018 Sep 13.

Matthew Mossanen, Brigham and Women's Hospital, Harvard Medical School, Center for Surgery and Public Health, Brigham and Women's Hospital; and Dana-Farber Cancer Institute, Boston, MA; Joshua Caldwell, Harvard Medical School, Boston, MA; Guru Sonpavde, Dana-Farber Cancer Institute, Boston, MA; and Lisa Soleymani Lehmann, National Center for Ethics in Health Care, Veterans Health Administration, Washington, DC, and Harvard Medical School and Harvard T.H. Chan School of Public Health, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.18.00577DOI Listing
September 2018

Role of Checkpoint Inhibition in Localized Bladder Cancer.

Eur Urol Oncol 2018 08 30;1(3):190-198. Epub 2018 May 30.

Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euo.2018.05.002DOI Listing
August 2018

Improving the Cost Efficiency of PD-1/PD-L1 Inhibitors for Advanced Urothelial Carcinoma: A Major Role for Precision Medicine?

Eur Urol 2018 07 10;74(1):63-65. Epub 2018 Apr 10.

Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2018.03.015DOI Listing
July 2018

Taxane chemotherapy vs antiandrogen agents as first-line therapy for metastatic castration-resistant prostate cancer.

BJU Int 2018 06 6;121(6):871-879. Epub 2018 Mar 6.

Sanofi, Bridgewater, NJ, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bju.14152DOI Listing
June 2018

The effect of treatment at minority-serving hospitals on outcomes for bladder cancer.

Urol Oncol 2018 05 15;36(5):238.e7-238.e17. Epub 2018 Feb 15.

Division of Urological Surgery, Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10781439183001
Publisher Site
http://dx.doi.org/10.1016/j.urolonc.2018.01.010DOI Listing
May 2018

Current Staging Strategies for Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Cell Carcinoma.

Urol Clin North Am 2018 May;45(2):143-154

Division of Urology, Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, 45 Francis Street, Boston, MA 02111, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ucl.2017.12.001DOI Listing
May 2018

Effect of Single-agent Daily Prednisone on Outcomes and Toxicities in Metastatic Castration-resistant Prostate Cancer: Pooled Analysis of Prospective Studies.

Clin Genitourin Cancer 2018 04 27;16(2):e277-e287. Epub 2017 Dec 27.

Dana Farber Cancer Institute, Boston, MA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2017.12.006DOI Listing
April 2018

Of Chemoimmunotherapy Sequences and Delayed Disease-modifying Activity in Advanced Urothelial Carcinoma: Vetus Fit Novum.

Eur Urol 2018 02 28;73(2):153-155. Epub 2017 Sep 28.

Bladder Cancer Center, Dana Farber Cancer Institute, Boston, MA, USA.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S03022838173077
Publisher Site
http://dx.doi.org/10.1016/j.eururo.2017.09.012DOI Listing
February 2018

Promising immunotherapy for prostate cancer.

Expert Opin Biol Ther 2018 02 12;18(2):109-120. Epub 2017 Dec 12.

b Department of Medical Oncology, GU section , Dana Farber Cancer Institute , Boston , MA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2018.1406916DOI Listing
February 2018

The prospects for combination therapy with capecitabine in the rapidly evolving treatment landscape of renal cell carcinoma.

Expert Opin Investig Drugs 2018 02 24;27(2):163-170. Epub 2018 Jan 24.

b Department of Medicine, Division of Hematology and Oncology , University of Alabama at Birmingham Comprehensive Cancer Center , Birmingham , AL , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13543784.2018.1427731DOI Listing
February 2018

JAVELIN: avelumab another spear to fight urothelial carcinoma.

Lancet Oncol 2018 01 5;19(1):5-7. Epub 2017 Dec 5.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S14702045173090
Publisher Site
http://dx.doi.org/10.1016/S1470-2045(17)30901-4DOI Listing
January 2018

Overview of Current and Future Adjuvant Therapy for High-Risk Localized Renal Cell Carcinoma.

Curr Treat Options Oncol 2018 01 18;19(1). Epub 2018 Jan 18.

Department of Medical Oncology, Genitourinary Oncology Section, Dana-Farber Cancer Institute, 450 Brookline Avenue, D1230F, Boston, MA, 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-018-0522-4DOI Listing
January 2018

Update of systemic immunotherapy for advanced urothelial carcinoma.

Urol Oncol 2017 12 25;35(12):678-686. Epub 2017 Oct 25.

Dana Farber Cancer Institute, Boston, MA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2017.09.021DOI Listing
December 2017

Emerging first line treatment options for bladder cancer: a review of phase II and III therapies in the pipeline.

Expert Opin Emerg Drugs 2017 12 19;22(4):347-355. Epub 2017 Dec 19.

b Dana Farber Cancer Institute , Boston , MA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14728214.2017.1416092DOI Listing
December 2017

The biology of prostate cancer metastases: does oligo differ from polymetastatic?

Authors:
Guru Sonpavde

Curr Opin Urol 2017 Nov;27(6):542-546

Section of Medical Oncology, Department of Medicine, University of Alabama at Birmingham (UAB) Comprehensive Cancer Center, Birmingham, Alabama, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOU.0000000000000434DOI Listing
November 2017

Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma.

Eur Urol 2017 10 14;72(4):557-564. Epub 2017 Apr 14.

Department of Medical Oncology, Dana-Farber Cancer Institute/Brigham and Women's Cancer Center, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2017.03.046DOI Listing
October 2017

Prevalence of Measurable Disease in Metastatic Castration-resistant Prostate Cancer.

Clin Genitourin Cancer 2017 10 26;15(5):534-539. Epub 2017 Apr 26.

University of Alabama, Birmingham, School of Medicine, Birmingham, AL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2017.04.020DOI Listing
October 2017

Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naïve, Metastatic, Castration-Resistant Prostate Cancer.

J Clin Oncol 2017 Oct 20;35(28):3181-3188. Epub 2017 Jun 20.

Emmanuel S. Antonarakis and Mario A. Eisenberger, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Scott T. Tagawa, Giuseppe Galletti, Daniel Worroll, Karla Ballman, Ada Gjyrezi, Shinsuke Tasaki, Luigi Portella, Yang Bai, Brian J. Kirby, David M. Nanus, and Paraskevi Giannakakou, Weill Cornell Medicine/Meyer Cancer Center; Che-Kai Tsao, Mount Sinai Medical Center, New York; Timothy B. Lannin, Shalu Suri, Conor N. Gruber, Erica D. Pratt, and Brian J. Kirby, Cornell University, Ithaca, NY; Marie Vanhuyse, Medical Oncology, Montréal General Hospital; Fred Saad, University of Montreal Hospital Center, Montreal; John Stewart, Atef Zaher, and Wei Zhou, Sanofi, Laval, Quebec, Canada; Guru Sonpavde, University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL; Scott North, University of Alberta, Cross Cancer Institute, Edmonton, Alberta, Canada; Costantine Albany, Indiana University School of Medicine, Indianapolis, IN; and Ted Szatrowski, Sanofi, Bridgewater, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.72.4138DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5791829PMC
October 2017

Editorial Comment.

Authors:
Guru Sonpavde

Urology 2017 10 30;108:140-141. Epub 2017 Aug 30.

Department of Medicine, Section of Hematology-Oncology, University of Alabama at Birmingham (UAB), Birmingham, AL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urology.2017.05.059DOI Listing
October 2017

Editorial comment.

Urology 2017 08 22;106:124. Epub 2017 Jun 22.

Brigham and Women's Hospital and Harvard Medical School, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urology.2017.04.050DOI Listing
August 2017

PSA declines and survival in patients with metastatic castration-resistant prostate cancer treated with enzalutamide: A retrospective case-report study.

Medicine (Baltimore) 2017 Jun;96(24):e6817

aDepartment of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy bDepartment of Medicine, University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL cMcMaster University, Hamilton, Ontario, Canada dDepartment of Emergency and Organ Transplantation, Urology, Andrology and Kidney Transplantation Unit, University of Bari, Bari eDivision of Medical Oncology, Department of Uro-Gynecological Oncology, Istituto Nazionale Tumori Fondazione G. Pascale fUnità Operativa Sperimentazioni Cliniche Oncologia, Azienda Ospedaliera di Rilievo Nazionale 'Antonio Cardarelli' Naples gMedical Oncology Department, G. Rummo Hospital, Benevento hDepartment of Medical Oncology, Casa Sollievo della Sofferenza Hospital, Medical Oncology, San Giovanni Rotondo iOspedale di Vallo della Lucania, Vallo Della Lucania, Salerno, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000006817DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5478302PMC
June 2017

Which checkpoint inhibitor? An embarrassment of riches for bladder cancer.

Immunotherapy 2017 05;9(6):463-466

Department of Internal Medicine, Division of Medical Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2017-0033DOI Listing
May 2017

Drug development in prostate cancer: time to embrace RECIST?

Lancet Oncol 2017 04 8;18(4):419-421. Epub 2017 Mar 8.

Duke Cancer Institute, Division of Medical Oncology, Department of Medicine, Durham, NC, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(17)30149-3DOI Listing
April 2017

PD-1 and PD-L1 Inhibitors as Salvage Therapy for Urothelial Carcinoma.

Authors:
Guru Sonpavde

N Engl J Med 2017 03 17;376(11):1073-1074. Epub 2017 Feb 17.

From the University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMe1701182DOI Listing
March 2017

Circulating Tumor Cells in Advanced Prostate Cancer: Time to Move from Prognostic to Predictive Ability.

Eur Urol 2017 02 1;71(2):172-173. Epub 2016 Sep 1.

Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2016.08.053DOI Listing
February 2017

Immunotherapy of advanced renal cell carcinoma: Current and future therapies.

Hum Vaccin Immunother 2016 12 5;12(12):2997-3004. Epub 2016 Aug 5.

c Huntsman Cancer Institute , Salt Lake City , UT , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/21645515.2016.1212794DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5215367PMC
December 2016

Immunotherapy for Renal Cancer: Sequencing and Combinations.

Eur Urol Focus 2016 Dec 20;2(6):582-588. Epub 2017 Apr 20.

Department of Medicine, Section of Hematology-Oncology, University of Alabama at Birmingham (UAB), Birmingham, AL, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euf.2017.04.002DOI Listing
December 2016

Emerging Systemic Therapies for the Management of Penile Cancer.

Urol Clin North Am 2016 Nov 3;43(4):481-491. Epub 2016 Sep 3.

Section of Medical Oncology, Department of Medicine, UAB Comprehensive Cancer Center, 1802 6th Avenue South, NP2540B, Birmingham, AL 35294, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ucl.2016.06.009DOI Listing
November 2016

Vaccine therapy in renal cell carcinoma: attempting to leap over a rising bar.

Lancet Oncol 2016 11 3;17(11):1477-1478. Epub 2016 Oct 3.

Department of Medicine, Section of Hematology-Oncology, University of Alabama at Birmingham Cancer Center, Birmingham, AL, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(16)30493-4DOI Listing
November 2016

Contemporary molecular tests for prognosis and treatment guidance for castration-resistant prostate cancer.

Expert Rev Mol Diagn 2016 10 28;16(10):1113-1120. Epub 2016 Sep 28.

c Comprehensive Cancer Center, University of Alabama at Birmingham (UAB) , Department of Medicine, Section of Hematology-Oncology , Birmingham , AL , USA.

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14737159.2016.1
Publisher Site
http://dx.doi.org/10.1080/14737159.2016.1240031DOI Listing
October 2016

NCCN Guidelines Insights: Bladder Cancer, Version 2.2016.

J Natl Compr Canc Netw 2016 10;14(10):1213-1224

From Vanderbilt-Ingram Cancer Center; Moffitt Cancer Center; Huntsman Cancer Institute at the University of Utah; Patient Advocate; Mayo Clinic Cancer Center; Stanford Cancer Institute; Massachusetts General Hospital Cancer Center; University of Colorado Cancer Center; UCSF Helen Diller Family Comprehensive Cancer Center; Fox Chase Cancer Center; Roswell Park Cancer Institute; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Memorial Sloan Kettering Cancer Center; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute; Duke Cancer Institute; UC San Diego Moores Cancer Center; Dana-Farber/Brigham and Women's Cancer Center; Robert H. Lurie Comprehensive Cancer Center of Northwestern University; Fred & Pamela Buffett Cancer Center; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; University of Michigan Comprehensive Cancer Center; City of Hope Comprehensive Cancer Center; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; Yale Cancer Center/Smilow Cancer Hospital; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; University of Washington/Seattle Cancer Care Alliance; The University of Texas MD Anderson Cancer Center; University of Alabama at Birmingham Comprehensive Cancer Center; and National Comprehensive Cancer Network.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5379654PMC
http://dx.doi.org/10.6004/jnccn.2016.0131DOI Listing
October 2016

Role of Chemotherapy and Mechanisms of Resistance to Chemotherapy in Metastatic Castration-Resistant Prostate Cancer.

Clin Med Insights Oncol 2016 9;10(Suppl 1):57-66. Epub 2016 Oct 9.

Division of Hematology-Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4137/CMO.S34535DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5065075PMC
October 2016

Circulating Biomarkers in Bladder Cancer.

Bladder Cancer 2016 Oct 27;2(4):369-379. Epub 2016 Oct 27.

Department of Medicine, Section of Hematology-Oncology, University of Alabama at Birmingham (UAB) , Birmingham, AL, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/BLC-160075DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5181678PMC
October 2016

Reply to L.J. Eapen et al.

Authors:
Guru Sonpavde

J Clin Oncol 2016 09 18;34(26):3228-9. Epub 2016 Jul 18.

University of Alabama School of Medicine and Veterans Affairs Medical Center, Birmingham, AL

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.68.3094DOI Listing
September 2016

Obesity and Outcomes in Patients with Metastatic Urothelial Carcinoma.

Bladder Cancer 2016 Jul 27;2(3):341-349. Epub 2016 Jul 27.

Department of Medicine, Division of Hematology/Oncology, Tisch Cancer Institute , Icahn School of Medicine at Mount Sinai, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/BLC-160047DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4969712PMC
July 2016